Cerity Partners LLC Purchases 8,725 Shares of Guardant Health, Inc. (NASDAQ:GH)

Cerity Partners LLC grew its stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 6.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 145,475 shares of the company's stock after purchasing an additional 8,725 shares during the period. Cerity Partners LLC owned about 0.12% of Guardant Health worth $6,197,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of GH. NewEdge Advisors LLC raised its stake in Guardant Health by 13.5% in the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock valued at $59,000 after purchasing an additional 230 shares during the last quarter. Summit Investment Advisors Inc. raised its stake in Guardant Health by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 12,346 shares of the company's stock valued at $377,000 after purchasing an additional 391 shares during the last quarter. GF Fund Management CO. LTD. raised its stake in Guardant Health by 22.0% in the 1st quarter. GF Fund Management CO. LTD. now owns 3,164 shares of the company's stock valued at $135,000 after purchasing an additional 570 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Guardant Health by 5.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,488 shares of the company's stock valued at $931,000 after purchasing an additional 1,502 shares during the last quarter. Finally, Values First Advisors Inc. raised its stake in Guardant Health by 5.5% in the 1st quarter. Values First Advisors Inc. now owns 29,597 shares of the company's stock valued at $1,263,000 after purchasing an additional 1,538 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.

Guardant Health Stock Performance

Shares of GH stock traded down $0.82 during mid-day trading on Friday, hitting $46.46. 1,769,359 shares of the stock traded hands, compared to its average volume of 2,181,257. Guardant Health, Inc. has a twelve month low of $20.14 and a twelve month high of $53.42. The firm has a market cap of $5.76 billion, a price-to-earnings ratio of -13.71 and a beta of 1.44. The company's 50-day simple moving average is $46.30 and its 200-day simple moving average is $44.38.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.08. The business had revenue of $203.47 million for the quarter, compared to analysts' expectations of $189.91 million. The business's quarterly revenue was up 20.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.46) EPS. Analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Meghan V. Joyce sold 3,337 shares of the company's stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $47.22, for a total value of $157,573.14. Following the sale, the director directly owned 11,150 shares in the company, valued at approximately $526,503. This represents a 23.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Ian T. Clark sold 6,672 shares of the business's stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $48.38, for a total value of $322,791.36. Following the completion of the transaction, the director directly owned 9,851 shares in the company, valued at $476,591.38. The trade was a 40.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 342,300 shares of company stock valued at $17,082,238 in the last ninety days. Company insiders own 6.10% of the company's stock.

Analyst Upgrades and Downgrades

GH has been the subject of a number of recent analyst reports. Stephens reissued an "overweight" rating and set a $55.00 price objective on shares of Guardant Health in a research report on Wednesday, March 26th. UBS Group raised their target price on Guardant Health from $65.00 to $70.00 and gave the company a "buy" rating in a report on Thursday, May 1st. TD Securities lifted their price objective on Guardant Health from $56.00 to $60.00 and gave the company a "buy" rating in a research note on Thursday, May 1st. Evercore ISI raised Guardant Health to a "strong-buy" rating in a research report on Monday, July 14th. Finally, Scotiabank reissued an "outperform" rating on shares of Guardant Health in a research report on Monday, May 5th. Twenty investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Guardant Health has an average rating of "Buy" and a consensus price target of $54.45.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.